US3981910A - Sulfur containing trialkoxybenzoylamino carboxylic acids - Google Patents

Sulfur containing trialkoxybenzoylamino carboxylic acids Download PDF

Info

Publication number
US3981910A
US3981910A US05/468,087 US46808774A US3981910A US 3981910 A US3981910 A US 3981910A US 46808774 A US46808774 A US 46808774A US 3981910 A US3981910 A US 3981910A
Authority
US
United States
Prior art keywords
carbon atoms
group
carboxy
alkyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/468,087
Other languages
English (en)
Inventor
Heribert Offermanns
Klaus Posselt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Deutsche Gold und Silber Scheideanstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsche Gold und Silber Scheideanstalt filed Critical Deutsche Gold und Silber Scheideanstalt
Priority to US05/687,504 priority Critical patent/US4055653A/en
Application granted granted Critical
Publication of US3981910A publication Critical patent/US3981910A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Definitions

  • the invention is directed to compounds of the formula: ##SPC2##
  • A is a straight or branched chain alkylene or alkylidene radical having 2 to 5 carbon atoms and which is substituted by an alkylthio group having 1 to 4 carbon atoms, a carboxymethyl thio group, a carboxyethyl thio group, an alkylsulfonyl group having 1 to 4 carbon atoms, a mercapto group, or the substituent on A together with --COR 4 forms a 4 to 7 membered thiolactone ring, or A is substituted by an acylmercapto group wherein the acyl is benzoyl, a benzoyl radical substituted with one, two or three alkoxy groups with 1 to 6 carbon atoms, an alkanoyl radical of 1 to 6 carbon atoms, an alkenoyl radical of 3 to 6 carbon atoms;
  • R 1 , R 2 and R 3 are the same or different and are alkyl groups of 1 to 5 carbon atoms and one of R 1 , R 2 and R 3 also can be hydrogen or the acyl radical of an alkanoic acid of 2 to 4 carbon atoms, and
  • R 4 is a hydroxy group or an alkoxy group with 1 to 5 carbon atoms and their pharmacologically acceptable salts.
  • the compounds are pharmacodynamically active and are suited for prophylaxis and treatment of heat illness such as cardiac ischemia, cardiac infarct, heart rhythm and circulatory disturbances.
  • alkylidene groups is meant a divalent alkyl group in which two single bonds (both bonds of A) go from a single carbon atom, i.e., for example, an ⁇ CH 2 group in which one or both hydrogen atoms are replaced by a straight or branched alkyl radical with 1 to 5 carbon atoms.
  • alkylidene groups are: CH 3 .sup.. CH ⁇ , CH 3 -CH 2 .sup.. CH ⁇ , CH 3 .sup.. (CH 2 ) 2 .sup.. CH ⁇ , CH 3 .sup.. (CH 2 ) 3 .sup.. CH ⁇ , CH 3 .sup.. (CH 2 ) 4 .sup..
  • A is a propylidene-1 group or a butylidene-1 group which is substituted in the 3 or 4 position by an alkylsulfonyl group, mercapto group or one of the above mentioned alkylated or acylated mercapto groups.
  • the alkyl group or alkoxy group as such or as part of another group generally consists of 1 to 3 carbon atoms.
  • R 1 is preferably methyl.
  • one of the radicals R 1 , R 2 and R 3 is hydrogen or an acyl radical then it is preferably R 2 .
  • the acyl radical for example is derived from a saturated aliphatic carboxylic acid with 2 or 3 carbon atoms.
  • any of the compounds of the invention can be made and used as the free base or in the form of a pharmaceutically acceptable salt, e.g., alkali metal and alkaline earth metal salts such as the sodium, potassium, magnesium, calcium, and barium salts, aluminum salts, zinc salts, iron salts, etc.
  • a pharmaceutically acceptable salt e.g., alkali metal and alkaline earth metal salts such as the sodium, potassium, magnesium, calcium, and barium salts, aluminum salts, zinc salts, iron salts, etc.
  • the compounds of the invention can take place using methods known in themselves including:
  • Typical compounds within formula II are: methionine, ethionine, methionine sulfone, ethionine sulfone, homocysteinethiolactone, cysteinethiolactone, methionine methyl ester, methionine ethyl ester, methionine propyl ester, methionine butyl ester, methionine isobutyl ester, methionine sec.
  • R' is an alkyl group or in the case of --OR' or SR' for example can also be a phenyl radical, a p-nitrophenyl radical, a cyanomethyl radical or a carboxymethyl radical; R" can be straight or branched chain alkyl group, an alkoxy group, a phenoxy group, a carbobenzoyl group or the group: ##SPC6##
  • X is halogen, it is preferably chlorine or bromine, in case R' or R" is alkyl or alkoxy, then these are preferably of lower molecular weight and contain 1 to 6 carbon atoms.
  • reaction of a compound of formula III or formula IV with a compound of formula II can take place in a conventional solvent or suspension agent such as water in a given case with addition of solvent facilitators, for example, lower aliphatic alcohols such as methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol or butyl alcohol, lower aliphatic ketones, e.g., acetone and methyl ethyl ketone, or dimethyl formamide, or in indifferent media.
  • solvent facilitators for example, lower aliphatic alcohols such as methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol or butyl alcohol, lower aliphatic ketones, e.g., acetone and methyl ethyl ketone, or dimethyl formamide, or in indifferent media.
  • an acid binding material such as alkali hydroxides, e.g., sodium carbonate and potassium carbonate, alkali bicarbonates, e.g., sodium bicarbonate and potassium bicarbonate, alkali bicarbonates, e.g., sodium bicarbonate and potassium bicarbonate alkali acetate, e.g., sodium acetate and potassium acetate, alkaline earth carbonates, e.g., magnesium carbonate, calcium carbonate and barium carbonate, trialkyl amines, e.g., triethylamine and tributylamine, pyridine and similar compounds or an excess of the compound of formula II.
  • the acid binding agent can also be used either alone or in admixture with other customary agents as solvents (for example, pyridine can be so used).
  • the starting material of formula II has a free carboxyl group
  • benzyl alcohol or a lower aliphatic alcohol having 1 to 6, especially 1 to 3 carbon atoms, such as any of the alcohols mentioned above, e.g., methyl alcohol, ethyl alcohol and isopropyl alcohol.
  • ester group can be split off from the end product with a base, for example, alcoholic alkali lye (for example, methanolic KOH or NaOH) or in a given case also by means of mineral acids such as hydrochloric acid or sulfuric acid in alcoholic or aqueous alcoholic solution at a temperature between 20° and 100°C.
  • a base for example, alcoholic alkali lye (for example, methanolic KOH or NaOH) or in a given case also by means of mineral acids such as hydrochloric acid or sulfuric acid in alcoholic or aqueous alcoholic solution at a temperature between 20° and 100°C.
  • this compound can also be added as an alkali salt (for example, the sodium salt or the potassium salt).
  • an alkali salt for example, the sodium salt or the potassium salt.
  • the symbol X of the reaction component of formula IV is a halogen atom.
  • the process is carried out in such amount that the free aminoacid is made into a paste with an about equal amount of water by weight and is then neutralized with about 30% soda lye. In a given case, excess soda lye is added as the acid acceptor. The mixture is cooled to -5 to +5°C., and then the trisubstituted benzoyl chloride gradually introduced with stirring while holding the temperature below 5°C.
  • the molar proportions of aminoacid to benzoyl chloride range from about 1 to 1.5:1.
  • the solution obtained is stirred for a long time (for example, 1 to 4 days).
  • the solution is decolorized with activated carbon and subsequently neutralized with dilute hydrochloric acid or sulfuric acid to a pH of 3.
  • the precipitate which falls out is filtered off, washed with water and dried and finally recrystallized from water to ethanol.
  • the compounds of formula II can also be added as salts (for example the hydrochloride) or in the form of a derivative in which the amino group to be reacted is present in an activated form.
  • One type of activation of the amino group for example, can take place by conversion into the isocyanate radical (OCN--A--COR 4 ) by means of phosgene according to the method described by Goldschmidt in Liebigs Annalen der Chemie, Vol.
  • the phosphorus azo compound can be obtained by action of 2 mols of the compound II or PCl 3 (see Goldschmidt, Angewandte Chemie, Vol. 67 (1955), pages 471-475, the entire disclosure of which is hereby incorporated by reference).
  • the process of the invention is carried out at temperatures between -10° and -150°C.
  • process conditions there can be employed all of the methods and process conditions customarily employed in amide and peptide synthesis (see for example Houben-Weyl "Methoden der organischen Chemie", Vol. 8 (1952), pages 655-661 and “Organic Reactions” vol. 12 (1962), pages 157 et seq. (the entire disclosure of the cited pages from Houben-Weyl and Organic Reactions is hereby incorporated by reference).
  • the reaction component of formula III contains a hydroxy group (one of the radicals R 1 through R 3 is H), it is suitable to protect this beforehand by the customary acyl or other easily splittable protective groups used for this purpose.
  • this type of protective group there can be used, for example lower, in a given case, halogen substituted aliphatic (e.g., alkyl) acyl radicals such as formyl, tert, butylcarboxy, acetyl, propionyl, or trifluoroacetyl, the benzyl group, benzyl groups substituted in the benzene nucleus by halogen or nitro groups, for example, the p-bromobenzyl and the p-nitrobenzyl group, the ⁇ -phenylethyl group, the carbobenzoxy group, the carbobenzthio group, the phthalyl radical, the trityl radical, the p-toluenesulfonyl radical and similar groups.
  • acyl groups can be split off by mineral acids such as hydrochloric acid or sulfuric acid, in alcoholic or aqueous-alcoholic solution, or by means of bases, for example, alcoholic alkali lye (for example, methanolic KOH) at temperatures between 20° and 100°C.
  • alcoholic alkali lye for example, methanolic KOH
  • the benzyl group, the carbobenzoxy radical as well as other reductive splittable radicals can be dehydrogenated with hydrogen in the presence of a hydrogenation catalyst (for example palladium, palladium-carbon) for example in ethanol, for example, under normal conditions.
  • a hydrogenation catalyst for example palladium, palladium-carbon
  • alkylating agent there can be considered for example, compounds of the formula R'Hal, ArSO 2 OR' and SO 2 (OR') 2 wherein Hal is a halogen atom (especially chlorine, bromine or iodine) and Ar is an aromatic radical such as phenyl or naphthyl which, for example, in a given case can be substituted by one or more lower alkyl groups and R' is an alkyl group with 1 to 4 carbon atoms.
  • Hal is a halogen atom (especially chlorine, bromine or iodine)
  • Ar is an aromatic radical such as phenyl or naphthyl which, for example, in a given case can be substituted by one or more lower alkyl groups and R' is an alkyl group with 1 to 4 carbon atoms.
  • Examples are p-toluene-sulfonic acid alkyl esters having 1 to 4 carbon atoms in the alkyl group, e.g., methyl p-toluenesulfonate, ethyl p-toluenesulfonate, butyl p-toluenesulfonate, methyl phenyl sulfonate, methyl alpha naphthylsulfonate, lower dialkyl sulfates, e.g., dimethyl sulfate, diethyl sulfate and similar esters.
  • p-toluene-sulfonic acid alkyl esters having 1 to 4 carbon atoms in the alkyl group, e.g., methyl p-toluenesulfonate, ethyl p-toluenesulfonate, butyl p-toluenesulfonate,
  • the mercaptans are generally added in the form of metal salts, e.g., alkali salts and silver salts, e.g., sodium methyl mercaptide, potassium ethyl mercaptide, sodium butyl mercaptide, silver methyl mercaptide.
  • metal salts e.g., alkali salts and silver salts
  • the reaction occurs at temperatures between 0° and 150°C. in inert solvents such as ethers, e.g., diethyl ether and dioxane, dimethyl formamide, dimethyl sulfoxide, aromatic hydrocarbons, e.g., benzene and toluene.
  • lactones those lactones which have a 4 to 7 membered lactone ring, for example, beta, gamma or delta lactones.
  • lactone in which the radical --A--COR 4 has the structure: ##STR1## where n is the number 1, 2, 3 or 4.
  • the reaction is carried out in customary solvents or suspension media at higher temperatures such as 100° to 250°C., preferably 150° to 200°C.
  • sodium or potassium mercaptides of alkyl mercaptans having 1 to 4 carbon atoms are used.
  • Esterified carboxyl groups present in the compounds obtained according to processes (a) and (b) can in a given case be saponified by treatment with hydrolyzing agents.
  • hydrolyzing agents for example, there can be read carbalkoxy groups whose alkoxy radicals have 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, e.g., carbmethoxy, carbethoxy, carbpropoxy, carbobutoxy, carbhexoxy, or the carbobenzoxy group to convert such groups to the free carboxyl group.
  • the saponification can take place for example with bases, (for example methanolic KOH) or in a given case also with mineral acids such as hydrochloric acid or sulfuric acid in alcoholic or aqueous alcoholic solution at temperatures between 20° and 100°C.
  • the compound of formula I which is obtained can be converted in conventional manner into its metal salts.
  • any pharmacologically acceptable metal salt especially alkali or alkaline earth metal salts such as sodium, potassium, magnesium and calcium salts.
  • alkali or alkaline earth metal salts such as sodium, potassium, magnesium and calcium salts.
  • such salts include the sodium salt of w-(3,4,5-trimethoxybenzoylamino) hexanoic acid, potassium salt of N-(3,4,5-trimethoxybenzoyl) glycine, calcium salt of D,L-N-(3,4,5-trimethoxybenzoyl)valine and magnesium salt of D,L-N-(3,4,5-trimethoxybenzoyl)phenylalanine.
  • the production of the salts can take place by reaction of the free acid with alkali or alkaline earth hydroxides, carbonates, alcoholates or acetates, e.g., sodium hydroxide, potassium, hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium methylate, potassium ethylate, calcium ethylate, magnesium ethylate, sodium acetate, potassium acetate, magnesium acetate or calcium acetate.
  • alkali or alkaline earth hydroxides, carbonates, alcoholates or acetates e.g., sodium hydroxide, potassium, hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium methylate, potassium ethylate, calcium ethylate, magnesium ethylate, sodium acetate, potassium acetate, magnesium acetate or calcium acetate.
  • optically active isomers which contain asymmetrical carbon atoms and as a rule are formed as racemates can be split into the optically active isomers in known manner, for example, by means of an optically active base.
  • optically active starting materials whereby there is obtained as the end product a corresponding optically active form.
  • the compounds of the invention are suited for the production of pharmaceutical compositions or preparations.
  • the pharmaceutical compositions or medicines contain one or more of the compounds of the invention as the active material, in a given case in admixture with other pharmacologically or pharmaceutically active materials, of which potassium and magnesium aspartate are preferred.
  • the production of the medicine can be accomplished using known and conventional pharmaceutical carriers and adjuvants.
  • the medicines can be used for example enterally, parenterally, orally, perlingually or in the form of sprays.
  • the administration can take place, for example, in the form of tablets, capsules, pills, dragees, plugs, liquids or aerosols.
  • liquids there can be used for example oily or aqueous solutions or suspensions, emulsions, or injectable aqueous or oily solutions or suspensions.
  • the activity of the compounds of the invention was investigated on narcotized dogs with acute induced coronary stenosis based on the method of G. V. Anrep and H. Hausler (J. Physiol. Vol. 65 (1928), pages 357-373). For example, it causes an improvement in the bloodflow in the supplying of narrowed coronary vessels.
  • dosage range for the activity there can be used for example 0.5 to 50 mg/kg intravenously and 1 to 200 mg/kg in oral application.
  • a chloroformic acid alkyl ester for example a lower alkyl ester such as ethyl chloroformate, methyl chloroformate or butyl chlor
  • Starting materials of formula IV wherein X is a group of the formula --O--SO 3 H, --O--PO(OH) 2 , --P(OR') 2 or --OAs(OR') 2 can be obtained for example from compounds for formula IV wherein X is a halogen atom by reaction with corresponding arsenious acid ester salts, phosphorous acid ester salts or primary sulfates or phosphates, e.g., diethyl sodium arsenite, diethyl sodium phosphite, sodium acid sulfate or monosodium phosphate.
  • Starting materials of formula IV wherein X is the group --OCO--OR" can be obtained for example from alkali metal salts of compounds of formula III by reacting them with compounds of the formula Hal--COOR" (where Hal is chlorine or bromine), e.g., by reacting sodium 3,4,5-trimethoxybenzoate with ethyl chloroformate.
  • the compounds of the invention are suited for the production of pharmaceutical compositions and preparations.
  • the pharmaceutical compositions or drugs contain as the active material one or several of the compounds of the invention, is a given case in admixture with other pharmacologically or pharmaceutically effective materials.
  • the production of the medicine can take place with the use of known and customary pharmaceutical assistants, carriers and diluents.
  • Such carriers and assistants as set forth for example are those recommended in the following literature as adjuvants for pharmacy, cosmetic and related fields such as in Ullmann's Encyklopedie der intor Chemie. Vol. 4 (1953), pages 1 to 39; Journal of Pharmaceutical Sciences, Vol. 52 (1963), pages 918 et seq.; H. va. Czetsch-Lindenwald, Hilfstoffe fer Pharmazie and angrenzende füre; Pharm. Ind. Vol. 2 (1961), pages 72 et seq.; Dr. H. P. Fiedler, Lexicon der Hilfstoffee fer Pharmazie, Kosmetik und angrenzende füre, Cantor Kg. Aulendorf i. Wurtt, 1971.
  • Such materials include gelatin, sugars such as sucrose or lactose, lecithin, pectin, starch (for example corn starch), tylose, talc, lycopodium silica (for example colloidal, glucose, cellulose, cellulose derivatives for example cellulose ethers in which the cellulose hydroxyl groups are particularly etherified with lower aliphatic alcohols and/or lower saturated oxyalcohols, for example, methyl hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose), stearates, e.g., methylstearate, and glyceryl stearate, magnesium and calcium salts of fatty acids with 12 to 22 carbon atoms, especially saturated acids (for example calcium stearate and magnesium stearate, emulsifiers, vegetable oils and fats, especially of plant origin (for example, peanut oil, castor oil, olive oil, sesame oil, cottonseed oil, corn oil, mono, di and tri-g
  • water or physiologically compatible organic solvents as for example, ethanol, 1,2-propylene glycol, polyglycols, e.g., diethylene glycol, triethylene glycol and dipropylene glycol and their derivatives, dimethyl sulfoxide, fatty alcohols, e.g., stearyl alcohol, cetyl alcohol and oleyl alcohol, triglycerides, e.g., glyceryl oleate, glyceryl stearate and glyceryl acetate, partial esters of glycerine, e.g., monoacetic diacetin, glyceryl monostearate, glyceryl distearate, glyceryl monopalmitate, paraffins and the like.
  • organic solvents as for example, ethanol, 1,2-propylene glycol, polyglycols, e.g., diethylene glycol, triethylene glycol and dipropylene glycol and their derivatives, dimethyl sulfox
  • solvent aids there can be used known and conventional solvent aids.
  • solvent aids there can be used for example polyoxyethylated fats, e.g., polyoxyethylated oleo triglyceride, linolized oleotriglyceride.
  • polyoxyethylated fats e.g., polyoxyethylated oleo triglyceride, linolized oleotriglyceride.
  • oleotriglycerides are olive oil, peanut oil, corn oil (see also Dr. H. P. Fiedler, "Lexikon der Hilfastoffe fer Pharmazie, Kosmetik und angrenzende füre", 1971, pages 191 to 195.
  • Polyoxyethylated means that the materials in question contain polyoxyethylene chains whose degree of polymerization is generally between 2 and 40 and especially between 10 and 20. Such materials can be obtained for example by reaction of the corresponding glyceride with ethylene oxide (for example 40 moles of ethylene oxide per mole of glyceride).
  • preservatives for example ethylenediamine tetraacetic acid
  • buffers for example aminoethyl sulfate
  • antioxidants for example ethylenediamine tetraacetic acid
  • complex formers for example ethylenediamine tetraacetic acid
  • antioxidants there can be used, for example, sodium meta bisulfite, ascorbic acid, gallic acid, alkyl gallates, e.g., methyl gallates and ethyl gallate, butyl hydroxyanisole, nordihydroguararetic acid, tocopherol such as tocopherol and synergists (materials which bind heavy metals by complex formation, for example, lecithin, ascorbic acid, phosphoric acid). The addition of synergists increases considerably the antioxidant activity of tocopherol.
  • preservatives there can be used for example sorbic acid, p-hydroxybenzoic acids (for example lower alkyl esters such as the methyl ester and the ethyl ester), benzoic acid, sodium benzoate, trichloroisobutyl alcohol, phenol, cresol, benzethonium chloride and formalin derivatives.
  • sorbic acid for example lower alkyl esters such as the methyl ester and the ethyl ester
  • benzoic acid sodium benzoate
  • trichloroisobutyl alcohol phenol, cresol, benzethonium chloride and formalin derivatives.
  • the pharmacological and galenical treatment of the compounds of the invention takes place according to the usual standard methods.
  • the active material or materials and assistants or carriers are well mixed by stirring or homogenization (for example, by means of colloid mill or ball mill), wherein the operation is generally carried out at temperatures between 20° and 80°C, preferably 20° to 50°C.
  • the drugs can be used for example orally, parenterally, rectally, vaginally, perlingually, or locally.
  • cardiaca such as heart active steroids, methyl xanthines and/or coronary spasmolytics.
  • the compounds of the invention of the dog heart in situ show (method according to Anrep and Hausler, J. Physiol. Vol. 65 (1928), pages 357-373) an improvement of ischemic insufficiency induced by artificial stenosisation of the aorta coronaris circumflexa.
  • This antiischemic activity is comparable to the activity of known medicines which contain nitroglycerine as the active material.
  • the lowest effective dosage in the above mentioned animal experiments is for example 10 mg/kg body weight orally, 1 mg/kg body weight intraveneously.
  • the compounds of the invention have utility in the prophylaxis and treatment of heart illnesses such as ischemic cardiopathy such as engina pectoris, heart infarct as well as blood flow disturbances in peripheral vessels such as diabetic angiopathy, Morbus Raynard, Claudicatio intermittent, apoplexy consequences, embolism or thrombosis.
  • ischemic cardiopathy such as engina pectoris
  • heart infarct as well as blood flow disturbances in peripheral vessels such as diabetic angiopathy, Morbus Raynard, Claudicatio intermittent, apoplexy consequences, embolism or thrombosis.
  • the pharmaceutical preparations generally contain between 10 and 300 mg of the active components of the invention.
  • the compounds can be delivered in the form of tablets, capsules, pills, dragees, suppositories, salves, gels, cremes, powders, liquids, dusts or aerosols.
  • liquids there can be used oily or aqueous solutions or suspensions, emulsions.
  • the preferred forms of use are tablets which contain between 10 and 50 mg of active material or solutions which contain between 0.5 and 5% of active material.
  • the amount of active component of the invention can be used for example in an amount of:
  • parenteral dispensation for example intravenously, intramuscularly between 10 and 50 mg
  • the oral individual dosage in general is between about 10 and 200 mg/kg body weight; the parenteral dosage is between about 1 to 20 mg/kg body weight.
  • the drugs can be used in human medicine, in veterinary medicine, e.g., to treat cats, dogs, horses, sheep, cattle, goats and pigs or in agriculture.
  • the drugs can be used alone or in admixture with other pharmacologically active materials.
  • the free acids can also be used as curing agents for melamine-formaldehyde resin.
  • the potassium salt was obtained as follows:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
US05/468,087 1973-05-15 1974-05-08 Sulfur containing trialkoxybenzoylamino carboxylic acids Expired - Lifetime US3981910A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/687,504 US4055653A (en) 1973-05-15 1976-05-18 Sulfur containing trialkoxybenzoylamino carboxylic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
OE4232/73 1973-05-15
AT423273A AT326111B (de) 1973-05-15 1973-05-15 Verfahren zur herstellung von neuen n-alkoxybenzoylaminosäuren, deren c1-c5-alkestern und zugehorigen thiolactonen und deren salzen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US05/687,504 Continuation-In-Part US4055653A (en) 1973-05-15 1976-05-18 Sulfur containing trialkoxybenzoylamino carboxylic acids

Publications (1)

Publication Number Publication Date
US3981910A true US3981910A (en) 1976-09-21

Family

ID=3561351

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/468,087 Expired - Lifetime US3981910A (en) 1973-05-15 1974-05-08 Sulfur containing trialkoxybenzoylamino carboxylic acids

Country Status (19)

Country Link
US (1) US3981910A (enrdf_load_stackoverflow)
JP (1) JPS5018435A (enrdf_load_stackoverflow)
AR (1) AR203647A1 (enrdf_load_stackoverflow)
AT (1) AT326111B (enrdf_load_stackoverflow)
BE (1) BE814970A (enrdf_load_stackoverflow)
CA (1) CA1013751A (enrdf_load_stackoverflow)
CH (1) CH603561A5 (enrdf_load_stackoverflow)
CS (1) CS181265B2 (enrdf_load_stackoverflow)
DD (1) DD114063A5 (enrdf_load_stackoverflow)
DE (1) DE2422923A1 (enrdf_load_stackoverflow)
ES (1) ES426296A1 (enrdf_load_stackoverflow)
FR (1) FR2229408B1 (enrdf_load_stackoverflow)
GB (1) GB1426977A (enrdf_load_stackoverflow)
HU (1) HU168499B (enrdf_load_stackoverflow)
IL (1) IL44837A (enrdf_load_stackoverflow)
NL (1) NL7406454A (enrdf_load_stackoverflow)
SE (1) SE397192B (enrdf_load_stackoverflow)
SU (1) SU534182A3 (enrdf_load_stackoverflow)
ZA (1) ZA743078B (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559360A (en) * 1983-11-23 1985-12-17 Magis Farmaceutici S.R.L. Cysteine derivatives, a process for their preparation, and pharmaceutical compositions which contain them
US5061700A (en) * 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2596631A (en) * 1948-06-14 1952-05-13 Schieffelin & Co Acylated amino acid silver salts
US3624143A (en) * 1968-05-10 1971-11-30 Merck & Co Inc Compounds of the class {62 -aralkylthio-substituted-{60 -amino acids
US3780095A (en) * 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2129877B1 (enrdf_load_stackoverflow) * 1971-03-18 1974-08-02 Fuveau Sa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2596631A (en) * 1948-06-14 1952-05-13 Schieffelin & Co Acylated amino acid silver salts
US3624143A (en) * 1968-05-10 1971-11-30 Merck & Co Inc Compounds of the class {62 -aralkylthio-substituted-{60 -amino acids
US3780095A (en) * 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559360A (en) * 1983-11-23 1985-12-17 Magis Farmaceutici S.R.L. Cysteine derivatives, a process for their preparation, and pharmaceutical compositions which contain them
US5061700A (en) * 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles

Also Published As

Publication number Publication date
BE814970A (fr) 1974-11-13
AU6897274A (en) 1975-11-20
SU534182A3 (ru) 1976-10-30
IL44837A (en) 1977-11-30
FR2229408A1 (enrdf_load_stackoverflow) 1974-12-13
CA1013751A (en) 1977-07-12
NL7406454A (enrdf_load_stackoverflow) 1974-11-19
HU168499B (enrdf_load_stackoverflow) 1976-05-28
GB1426977A (en) 1976-03-03
CH603561A5 (enrdf_load_stackoverflow) 1978-08-31
AR203647A1 (es) 1975-09-30
ZA743078B (en) 1975-05-28
ATA423273A (de) 1975-02-15
AT326111B (de) 1975-11-25
FR2229408B1 (enrdf_load_stackoverflow) 1977-07-08
DE2422923A1 (de) 1974-12-05
CS181265B2 (en) 1978-03-31
SE397192B (sv) 1977-10-24
ES426296A1 (es) 1976-07-01
JPS5018435A (enrdf_load_stackoverflow) 1975-02-26
IL44837A0 (en) 1974-07-31
DD114063A5 (enrdf_load_stackoverflow) 1975-07-12

Similar Documents

Publication Publication Date Title
US4051141A (en) Thieno[3,2-c]pyridine derivatives
US4383994A (en) Homocysteine thiolactone salts and use thereof as anti-neoplastic agents
US3649679A (en) Substituted phenylalkanoic acid derivatives ii
US4032534A (en) Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
US4761404A (en) Phospholipid analogs useful as PAF synthesis inhibitors
US4055653A (en) Sulfur containing trialkoxybenzoylamino carboxylic acids
US3981910A (en) Sulfur containing trialkoxybenzoylamino carboxylic acids
US4256752A (en) Treatment of ulcers with acylated aminoalkyl cyanoguanidines containing a heterocyclic residue
US2844510A (en) Phosphoric acid derivatives of 1-phenyl-2, 3-dimethyl-4-amino-5-pyrazolone
US4147805A (en) Alkylthiophenoxyalkylamines and the pharmaceutical use thereof
US2561385A (en) Aranoalkyl-z-tmenyl-cycloalkenyl
Tullar et al. Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects
US3970694A (en) Cycloalkyl phenoxy carboxylic acid derivatives
US3576830A (en) Amides containing sulfur
US3914219A (en) 3-Alkyl-4-sulfamoyl-aniline compounds
US4314076A (en) Cystamine derivatives suitable for use as medicaments
US4576760A (en) Hydroquinone sulfate derivatives and production thereof
US4269855A (en) (3-Alkylamino-2-hydroxypropoxy)-furan-2-carboxylic acid anilides and physiologically tolerated acid addition salts thereof and medicaments containing them
US3876683A (en) (n-carboxymethyl)biphenyl acetamides
JPS6299329A (ja) 皮膚用抗炎症組成物
US4272529A (en) O-Alcoxycarbonylphenyl esters of anthranilic acid with therapeutical activity, method for their preparation and related pharmaceutical composition
US4161533A (en) 5-Sulfamoyl-orthanilic acids and process for their preparation
PL117941B1 (en) Process for preparing derivatives of thieno-/2,3-c/and-/3,2-c/pyridinespiridina
US3547948A (en) 4-amino-1,2-dithiolane-4-carboxylic acids
PL81176B1 (enrdf_load_stackoverflow)